MediPal Holdings (TSE:7459) Looks Undervalued, Is The Discount To Fair Value Justified?

MediPal Holdings (TSE:7459) drew investor attention after its recent share price move, with the stock closing at ¥2,906.5 as return figures over the past year presented a mixed picture.

MediPal Holdings has seen short term share price momentum cool, with the stock down 2.92% over the past day and slightly lower over the past week. However, the 90 day share price return of 9.68% and 1 year total shareholder return of 13.94% point to steadier underlying strength.

Compare MediPal Holdings with a hand picked group of healthcare distributors and similar operators by screening for list of solid balance sheet and fundamentals (21 results) that match your risk and quality checklist.

MediPal Holdings looks like a broad based healthcare distributor with steady long term returns. After the latest move, the real test is whether that quality is already fully reflected in the current share price.

Price-to-Earnings of 12.8x: Is it justified?

MediPal Holdings currently trades on a P/E of 12.8x, which leaves the stock looking inexpensive compared with several reference points while the share price sits at ¥2,906.5.

The P/E ratio compares the market value of the equity with its earnings. For a broad based healthcare distributor like MediPal Holdings, this metric helps investors weigh how much they are paying for each unit of profit in a sector where mature, slower growth and dependable cash generation are common.

Several data points support this valuation. MediPal Holdings is described as trading at good value compared to peers and the wider JP Healthcare group, with its 12.8x P/E below the industry average of 14.1x and also under the peer average of 13.1x. The estimated fair P/E of 18.9x is materially higher than the current level. This indicates that the market is pricing its earnings at a sizeable discount relative to that fair ratio.

Explore the SWS fair ratio for MediPal Holdings.

Result: Price-to-Earnings of 12.8x (UNDERVALUED)

Still, the investment case around MediPal Holdings could be tested if earnings growth slows from recent levels or if pharmaceutical distribution margins come under pressure.

Find out about the key risks to this MediPal Holdings narrative.

Another Look At MediPal Holdings Using Cash Flows

Earnings multiples point one way, but the SWS DCF model offers a different lens. On that approach, MediPal Holdings at ¥2,906.5 trades at a discount to an estimated future cash flow value of ¥3,986.95, which frames the current price as potentially undervalued. How much weight do you put on cash flows versus reported earnings?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out MediPal Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 17 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of signals around MediPal Holdings leaves you undecided, review the data, test the assumptions, and determine your own view. To see which potential upsides other investors are watching, review the 5 key rewards

Looking for more investment ideas beyond MediPal Holdings?

If MediPal Holdings has sparked your interest, do not stop here. Use the Simply Wall St screener to map out fresh, high quality opportunities that fit your style.

• Target resilient balance sheets and dependable fundamentals by scanning a curated list of solid balance sheet and fundamentals (21 results) that is aligned with more cautious risk profiles.
• Hunt for mispriced quality by reviewing a focused 17 high quality undervalued stocks that filters for strong businesses trading below their estimated worth.
• Build potential income streams by zeroing in on a 14 dividend fortresses that screens for higher yields with supporting fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com